Descripción de la empresa
Exicure, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, with a primary historical focus on developing nucleic acid therapies that target ribonucleic acid against validated targets. The company is headquartered in Redwood City, California, and was founded in 2011, though it currently does not possess significant ongoing operations to support its biotechnology development initiatives. As of the latest available data, the enterprise holds a market capitalization of $25.69M, employs a workforce of 8 individuals, and reports no annual revenue due to its lack of significant operational activity. This valuation indicates that the company exists primarily as a shell entity or a pre-revenue biotechnology platform, where the market capitalization reflects speculative value rather than established cash flows or sales volume. The absence of significant operations suggests the company is in a dormant or transitional phase, relying on past asset values rather than current business model execution to justify its public listing.
Salud financiera
The company's financial statements reveal a Net Income of $-4,946,000 over the trailing twelve months, while Revenue and EBITDA are both reported as N/A or effectively zero in terms of profitability, resulting in an EBITDA of $-9,875,000. The gap between non-existent revenue and substantial net losses indicates a cost structure entirely driven by operating expenses without any corresponding revenue generation to offset them. Free Cash Flow stands at $-4,212,750, which signifies a complete lack of financial flexibility and an inability to fund operations or investments from internal cash generation. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company generates no profit on its sales or operations and incurs losses across every layer of its financial structure. Despite these losses, the company maintains $3.75M in cash against a debt load of $176,000, resulting in a Debt to Equity ratio of 4.48. The balance sheet appears leveraged due to the high debt-to-equity ratio, yet the substantial cash balance provides a buffer against short-term solvency concerns. Liquidity is further assessed by a Current Ratio of 1.19, which suggests the company can technically meet its short-term obligations with its current assets, though this is precarious given the negative operating performance. Return on Equity is -92.5% and Return on Assets is -43.5%, metrics that reveal management is currently destroying shareholder value and failing to utilize assets to generate positive returns.
Evaluación de valoración
Valuation multiples for Exicure, Inc. present a complex picture given the company's lack of profitability, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -5.23. The negative forward P/E implies that the market is pricing in expected losses rather than earnings growth, as the company is not yet profitable enough to generate a traditional price-to-earnings multiple. The Price to Book ratio is 6.54, indicating that the stock trades at a significant premium relative to its net asset value, which is unusual for a biotechnology company with limited operations and negative earnings. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -2.24, further underscore the speculative nature of the stock, as these figures cannot be normalized by positive earnings or sales. The stock has traded within a 52-week range with a high of $12.85 and a low of $3.10, suggesting significant price volatility over the past year. The current price sits somewhere within this wide range, reflecting the high-risk profile of holding a biotechnology stock with no significant operations. The Beta is recorded at 4.01, which indicates that the stock's price volatility is four times that of the broader market, making it an extremely sensitive instrument to market sentiment and investor risk appetite.
Growth & Income
Exicure, Inc. reports N/A for Revenue Growth (YoY) and N/A for Earnings Growth (YoY), as the company does not generate revenue or earnings to measure growth trajectories. Consequently, there is no data to suggest whether earnings are growing faster or slower than revenue, as both metrics are absent from the financial records. As a non-dividend payer, the company offers a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company is in a position where it must rely on its existing cash reserves to fund operations and research, rather than reinvesting earnings from profitable activities. The overall growth and income profile is characterized by a complete absence of income generation and measurable growth, positioning the asset as a pure speculation on future biotechnology developments rather than a vehicle for capital appreciation through dividends or earnings expansion.